{"count": 2, "results": [{"_id": "36108773", "pmid": 36108773, "title": "Metformin inhibits the pathogenic functions of AChR-specific B and Th17 cells by targeting miR-146a.", "journal": "Immunol Lett", "authors": ["Hao Y", "Zhao W", "Chang L", "Chen X", "Liu C", "Liu Y", "Hou L", "Su Y", "Xu H", "Guo Y", "Sun Q", "Mu L", "Wang J", "Li H", "Han J", "Kong Q"], "date": "2022-10-01T00:00:00Z", "doi": "10.1016/j.imlet.2022.09.002", "meta_date_publication": "2022 Oct", "meta_volume": "250", "meta_issue": "", "meta_pages": "29-40", "score": 50270.117, "text_hl": "@CELLLINE_CVCL:1923 @@@EAMG@@@-specific Th17 and Treg cells had lower @GENE_MIR146A @GENE_100314241 @@@miR-146a@@@ levels, while @CELLLINE_CVCL:1923 @@@EAMG@@@-specific B cells had higher @GENE_MIR146A @GENE_100314241 @@@miR-146a@@@ levels, indicating that targeted intervention against @GENE_MIR146A @GENE_100314241 @@@miR-146a@@@ might have diametrically opposite effects. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@, a drug that was recently demonstrated to alleviate @<m>DISEASE_Myasthenia_Gravis_Autoimmune_Experimental</m> @DISEASE_MESH:D020720 @@@EAMG@@@, may rescue the functions of both Th17 cells and B cells by reversing the expression of @GENE_MIR146A @GENE_100314241 @@@miR-146a@@@. ", "citations": {"NLM": "Hao Y, Zhao W, Chang L, Chen X, Liu C, Liu Y, Hou L, Su Y, Xu H, Guo Y, Sun Q, Mu L, Wang J, Li H, Han J, Kong Q. Metformin inhibits the pathogenic functions of AChR-specific B and Th17 cells by targeting miR-146a. Immunol Lett. 2022 Oct;250():29-40. PMID: 36108773", "BibTeX": "@article{36108773, title={Metformin inhibits the pathogenic functions of AChR-specific B and Th17 cells by targeting miR-146a.}, author={Hao Y and Zhao W and Chang L and Chen X and Liu C and Liu Y and Hou L and Su Y and Xu H and Guo Y and Sun Q and Mu L and Wang J and Li H and Han J and Kong Q}, journal={Immunol Lett}, volume={250}, pages={29-40}}"}}, {"_id": "31437793", "pmid": 31437793, "title": "Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis.", "journal": "Int Immunopharmacol", "authors": ["Cui Y", "Chang L", "Wang C", "Han X", "Mu L", "Hao Y", "Liu C", "Zhao J", "Zhang T", "Zhang H", "Zhang Y", "Liu Y", "Zhao W", "Wang J", "Liu X", "Sun B", "Wang G", "Kong Q", "Han J", "Li H"], "date": "2019-10-01T00:00:00Z", "doi": "10.1016/j.intimp.2019.105822", "meta_date_publication": "2019 Oct", "meta_volume": "75", "meta_issue": "", "meta_pages": "105822", "score": 50070.527, "text_hl": "We first provided evidence that oral administration of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ attenuated the onset of @<m>DISEASE_Myasthenia_Gravis_Autoimmune_Experimental</m> @DISEASE_MESH:D020720 @@@EAMG@@@. ", "citations": {"NLM": "Cui Y, Chang L, Wang C, Han X, Mu L, Hao Y, Liu C, Zhao J, Zhang T, Zhang H, Zhang Y, Liu Y, Zhao W, Wang J, Liu X, Sun B, Wang G, Kong Q, Han J, Li H. Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis. Int Immunopharmacol. 2019 Oct;75():105822. PMID: 31437793", "BibTeX": "@article{31437793, title={Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis.}, author={Cui Y and Chang L and Wang C and Han X and Mu L and Hao Y and Liu C and Zhao J and Zhang T and Zhang H and Zhang Y and Liu Y and Zhao W and Wang J and Liu X and Sun B and Wang G and Kong Q and Han J and Li H}, journal={Int Immunopharmacol}, volume={75}, pages={105822}}"}}]}